These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11422496)

  • 1. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
    González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
    Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.
    Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI
    Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.
    Gümürdülü D; Zeren EH; Cagle PT; Kayasel uk F; Alparslan N; Kocabas A; Tuncer I
    Pathol Oncol Res; 2002; 8(3):188-93. PubMed ID: 12515999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
    Roberts F; Harper CM; Downie I; Burnett RA
    Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
    Kennedy AD; King G; Kerr KM
    J Clin Pathol; 1997 Oct; 50(10):859-62. PubMed ID: 9462271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
    Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
    J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
    Delahaye M; van der Ham F; van der Kwast TH
    Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
    Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
    Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
    King JE; Thatcher N; Pickering CA; Hasleton PS
    Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
    Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
    Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
    Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
    Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.